Stocks Health care HRTX
NASDAQ · Health careHeron Therapeutics, Inc. (HRTX)
Heron Therapeutics, Inc. brought in $151.2M of revenue over the twelve months to June 30, 2026, up 1.0% from a year earlier. It posted a net loss of $34M. In fiscal 2025 capital spending exceeded operating cash flow by $27.9M. At June 30, 2026 it held $20.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Heron Therapeutics, Inc.
- Net worth
- Heron Therapeutics, Inc. has a market value (market cap) of $70.4M at the latest share price, and shareholders' equity of $6.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $154.9M (+7.4% year on year), with a net loss of $20.2M. Over the 12 months to June 30, 2026: revenue $151.2M, net loss $34M.
- Cash flow
- In fiscal 2025 operations used $27.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Heron Therapeutics, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
What Heron Therapeutics, Inc. does
Heron Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HRTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $154.9M | -$20.2M | -$0.12 | -$27.9M |
| 2024 | $144.3M | -$13.6M | -$0.09 | -$24.2M |
| 2023 | $127M | -$110.6M | -$0.80 | -$60.3M |
| 2022 | $107.7M | -$182M | -$1.67 | -$148.7M |
| 2021 | $86.3M | -$220.7M | -$2.24 | -$206.4M |
| 2020 | $88.6M | -$227.3M | -$2.50 | -$191.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where HRTX ranks in Health care
Latest SEC filings
What Heron Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 29, 2026Material agreement8-KHeron Therapeutics entered into a multi-product development and license agreement with Long Grove Pharmaceuticals and Capstone Development Services.
- August 14, 2026
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 1.3% to $37.7M versus the same quarter last year; diluted EPS -$0.03 versus -$0.02.
- August 10, 2026
- June 25, 2026
- June 16, 2026
- June 2, 2026Other event 8-K
- May 13, 2026Passive stake changed SCHEDULE 13G/A
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 11% to $34.7M versus the same quarter last year; diluted EPS -$0.04 versus $0.01.
- May 11, 2026
Insider trades
What the people running Heron Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 6, 2026 | Hensley Mark EarlChief Operating Officer | Exercised options | 31,250 | - |
| August 6, 2026 | Hensley Mark EarlChief Operating Officer | Shares withheld for tax | 8,888 | $4.4K |
| July 31, 2026 | Collard Craig AChief Executive Officer, Director | Exercised options | 34,789 | - |
| July 31, 2026 | Duarte IraEVP, Chief Financial Officer | Exercised options | 11,694 | - |
| July 31, 2026 | Duarte IraEVP, Chief Financial Officer | Shares withheld for tax | 3,326 | $1.7K |
| July 31, 2026 | Forbes William PEVP, Chief Development Officer | Exercised options | 11,694 | - |
| July 31, 2026 | Forbes William PEVP, Chief Development Officer | Shares withheld for tax | 3,326 | $1.7K |
| July 31, 2026 | Hensley Mark EarlChief Operating Officer | Exercised options | 11,769 | - |
Who owns HRTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Rubric Capital Management LP13D, may seek influence with 1 related filers | 15.9% | October 17, 2025 |
| Clearline Capital LP13G, passive with 2 related filers | 6.7% | February 17, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 162 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rubric Capital Management LP | 30,046,828 | 0 |
| Clearline Capital LP | 11,383,961 | -851,278 |
| BlackRock, Inc. | 10,550,750 | +444,328 |
| Velan Capital Investment Management LP | 8,753,290 | 0 |
| Vanguard Capital Management LLC | 7,782,741 | -27,588 |
| Tejara Capital Ltd | 6,510,795 | +174,040 |
| Tang Capital Management LLC | 6,250,000 | 0 |
| Geode Capital Management, LLC | 4,270,980 | +260,893 |
| Millennium Management LLC | 4,070,101 | -3,560,426 |
| JW Asset Management, LLC | 3,751,073 | 0 |
| State Street Corp | 3,228,557 | -615,115 |
| UBS Group AG | 2,997,073 | +711,190 |
| Pale Fire Capital SE | 2,511,478 | -204,850 |
| Marshall Wace, Llp | 2,354,193 | new |
| Congress Park Capital LLC | 2,016,447 | -2,016,290 |
| Richmond Brothers, Inc. | 1,792,319 | +355,614 |
| Vanguard Portfolio Management LLC | 1,580,510 | +271,198 |
| Aqr Capital Management LLC | 1,553,857 | +912,270 |
| Renaissance Technologies LLC | 1,506,900 | -211,400 |
| Vanguard Fiduciary Trust Co | 1,365,119 | +212,405 |
Insiders
10 insiders reported holding 1,944,002 shares in total, about $721.2K at the last price.
| Holder | Shares |
|---|---|
| Collard Craig AChief Executive Officer, Director | 856,492 |
| Duarte IraEVP, Chief Financial Officer | 281,899 |
| Forbes William PEVP, Chief Development Officer | 241,173 |
| Hensley Mark EarlChief Operating Officer | 170,901 |
| Morgan AdamDirector | 123,737 |
| Cusack ThomasDirector | 53,960 |
| Johnson Craig ADirector | 53,960 |
| Christian WaageDirector | 53,960 |
| Kaseta MichaelDirector | 53,960 |
| Dissanaike SharmilaDirector | 53,960 |
Questions about HRTX
What does Heron Therapeutics, Inc. do?
Heron Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as HRTX. Its shares trade on NASDAQ under the ticker HRTX.
What is Heron Therapeutics, Inc.'s net worth?
Heron Therapeutics, Inc. has a market value (market cap) of $70.4M at the latest share price, and shareholders' equity of $6.9M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Heron Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $34M on revenue of $151.2M.
How much revenue does Heron Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Heron Therapeutics, Inc. reported revenue of $151.2M. That is 1.0% more than a year earlier.
When did Heron Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 29, 2026.
When is Heron Therapeutics, Inc.'s next earnings report?
Heron Therapeutics, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare HRTX with
Follow HRTX
Get an email when Heron Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Heron Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.